CRISPR Therapeutics AG (CRSP) Change in Cash (2015 - 2026)

CRISPR Therapeutics AG has disclosed Change in Cash across 12 years of filings, most recently posting -$132.0 million for Q2 2026.

• In Q2 2026, Change in Cash fell 217.51% year-over-year to -$132.0 million; the TTM figure through Jun 2026 stood at $94.2 million (up 132.39% YoY), while the FY2025 annual figure was $49.3 million, up 154.0% from the prior year.
• Change in Cash came in at -$132.0 million for Q2 2026 at CRISPR Therapeutics AG, down from $72.2 million in the prior quarter.
• In the past five years, Change in Cash ranged from a high of $317.9 million in Q1 2024 to a low of -$286.3 million in Q4 2022.
• Average Change in Cash over 5 years is -$35.6 million, with a median of -$22.2 million recorded in 2022.
• Year-over-year, Change in Cash sank 461.8% in 2022 and soared 3126.99% in 2023.
• Over 5 years, Change in Cash stood at -$286.3 million in 2022, then jumped by 51.61% to -$138.5 million in 2023, then soared by 152.4% to $72.6 million in 2024, then dropped by 15.88% to $61.1 million in 2025, then sank by 316.13% to -$132.0 million in 2026.
• Per Business Quant data, the three most recent Change in Cash figures were -$132.0 million in Q2 2026, $72.2 million in Q1 2026, and $61.1 million in Q4 2025.